Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...
This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...
GlobalData on MSN7d
Boehringer seeks approval for lung fibrosis drug following Phase III winThe Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
ECMO or ventilator use was the most significant predictor of mortality in patients undergoing lung transplant for idiopathic ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
A panel of experts, including Dr Rohit Aggarwal, Principal Investigator of the decentralized Myositis Interstitial Lung ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback